Other novel biochemical markers for prostate cancer risk assessment such as the prostate health index (PHI) [29] and prostate cancer antigen 3 (PCA3) [30] may reduce unnecessary biopsies to some extent, but cost, convenience and accessibility are barriers to widespread clinical application. Here, PCA3 is linked to prostate carcinoma.